Repligen (RGEN) to Release Earnings on Wednesday

Repligen (NASDAQ:RGENGet Rating) will post its quarterly earnings results before the market opens on Wednesday, April 27th. Analysts expect Repligen to post earnings of $0.72 per share for the quarter. Repligen has set its FY22 guidance at $3.21-3.30 EPS and its FY 2022 guidance at $3.210-$3.300 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Repligen (NASDAQ:RGENGet Rating) last posted its earnings results on Thursday, February 17th. The biotechnology company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.16. Repligen had a net margin of 19.13% and a return on equity of 10.58%. The company had revenue of $186.52 million during the quarter, compared to analysts’ expectations of $178.27 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. Repligen’s quarterly revenue was up 71.7% compared to the same quarter last year. On average, analysts expect Repligen to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

RGEN stock opened at $154.08 on Wednesday. The company has a 50 day moving average price of $178.53 and a 200 day moving average price of $223.97. Repligen has a fifty-two week low of $149.07 and a fifty-two week high of $327.32. The stock has a market capitalization of $8.39 billion, a PE ratio of 68.79 and a beta of 0.90.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Toroso Investments LLC boosted its position in shares of Repligen by 18.0% during the 4th quarter. Toroso Investments LLC now owns 936 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 143 shares in the last quarter. CWA Asset Management Group LLC acquired a new stake in Repligen in the fourth quarter valued at approximately $360,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Repligen in the fourth quarter valued at approximately $1,066,000. Vident Investment Advisory LLC boosted its position in Repligen by 15.0% in the fourth quarter. Vident Investment Advisory LLC now owns 4,488 shares of the biotechnology company’s stock valued at $1,189,000 after buying an additional 585 shares in the last quarter. Finally, Sei Investments Co. boosted its position in Repligen by 21.5% in the fourth quarter. Sei Investments Co. now owns 50,565 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 8,963 shares in the last quarter. Institutional investors and hedge funds own 86.25% of the company’s stock.

Several brokerages have recently issued reports on RGEN. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 price target for the company. in a report on Monday, February 21st. StockNews.com started coverage on shares of Repligen in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, SVB Leerink reduced their target price on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, February 18th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Repligen currently has an average rating of “Buy” and a consensus target price of $291.63.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Earnings History for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.